Endemic equilibrium cometh

Virus is close to reaching “endemic equilibrium” Update on BaliraUploaded 25-10-21Link to original Wefeafwa videohttps://www.youtube.com/watch?v=mV7a9MMFbRg&t=15sIf you would like to support our community health outreach in Uganda (100% of donations go directly to Wefwafwa)patreon:https://www.patreon.com/awmedicalvideosDonate: SENDWAVE/ WorldRemit /Western Union/Money GramMobile money number:+256785698803Country: UgandaRegistered name : Wefwafwa AndrewState: Eastern ugandaZip code:0000Wallet Service provider:MTNCity: Mbale cityplease email me when you send or to talk with me directly,wefandrew@gmail.comLondon School of Hygiene and Tropical Medicinehttps://www.telegraph.co.uk/news/2021/10/24/coronavirus-cases-slump-winter-say-scientists/Imminent drops in infectionsCases could fall to around 5,000 a day before ChristmasProf John Edmunds, Centre for the Mathematical Modelling of Infectious Diseases, LSHTMMember of SAGEOur model was projecting that cases would start to decline some time in the autumn. However, the model also suggests that cases may start to climb again in the spring, due to a combination of waning immunity and increased contactsCases currently being driven by high case rates in childrenVirus is close to reaching “endemic equilibrium” Recent oscillations in case rates will soon levelRishi Sunakat the moment the data does not suggest that we should be immediately moving to 'Plan BMaggie Throup, UK vaccines minister'Plan A' is working, situation where we need to beUnited StatesPfizer for children, 5 to 11, FDA votes for EMU tomorrowFrom first half of November2 shots, 3 weeks gapOne third of adult dose25,000 centres signed up for roll out28 million children in demographichttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotalhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-resultshttps://www.businesswire.com/news/home/20210920005452/en/https://www.fda.gov/media/153447/downloadResults are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of ageIn participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responsesPhase 2/3 studyUnited States, Finland, Poland, SpainChildren 6 months to 11 years of ageN = 2,268 5 to 11 years of ageReceived a 10 µg dose level in a two-dose regimenStrong SARS-CoV-2–neutralizing antibody response,one month after the second doseContinue to accumulate the safety and efficacy dataTopline readouts for the other two age cohorts from the trial, soonChildren 2-5 years of ageChildren 6 months to 2 years of ageAbout the Phase 1/2/3 Trial in ChildrenN = 4,500 children ages 6 months to 11 yearsMore than 90 clinical trial sitesChildren under 5 received a 3 µg doseTrial enrolled children with or without prior evidence of SARS-CoV-2 infectionONShttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsightsReduction in self-reported long COVID after vaccinationhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19vaccinationandselfreportedlongcovidintheuk/25october2021Identified themselves as experiencing persistent symptoms 12 weeks after first infectionA first vaccine dose was associated with an initial 13% decrease in self-reported long COVID,and a further 9% sustained decrease after receiving the second vaccinationNo evidence of differences in self-reported between Oxford/AstraZeneca vaccine, compared to Pfizer/BioNTech or Moderna vaccinesUK, 30 June to 17 October 2021Practice falls below thinkinghttps://www.ons.gov.uk/peoplepopul Learn more about your ad choices. Visit megaphone.fm/adchoices